Drug intelligence / Profile preview

NK cell enriched mononuclear cells

Development stage: Unknown
Lead developer: Nkarta
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NK cell enriched mononuclear cells refer to a type of cell therapy that involves enriching peripheral blood mononuclear cells (PBMCs) with natural killer (NK) cells, which are critical components of the innate immune system. NK cells are known for their ability to recognize and kill infected cells and cancer cells without prior antigen exposure. The enrichment process enhances the proportion of NK cells within the PBMCs, making them more effective in immunotherapy applications, particularly in treating cancers.

Beyond the preview

Go deeper on NK cell enriched mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK cell enriched mononuclear cells.

Explore the full profile